

The Evolution of SARS-CoV-2 Delta and Omicron Variants: Transmission Dynamics and Public Health Response

Prisha Sakhare

Abstract

The Delta (B.1.617.2) and Omicron (B.1.1.529) variants reshaped the COVID-19 pandemic. Delta brought high viral loads and more severe disease; Omicron spread even faster and evaded prior immunity. Although milder in vaccinated people, Omicron’s sheer scale strained healthcare systems worldwide. This literature review compares the two variants’ transmission dynamics and the public health responses they triggered. Both exposed gaps in genomic surveillance, unequal vaccine access, and the limits of single-intervention strategies. The evidence shows that transmissibility alone can overwhelm health systems, and that preparing for future variants requires adaptive policy, sustained surveillance and equitable access to vaccines.

SARS-CoV-2

Delta

Omicron

Transmission

Public health policy

Introduction

- SARS-CoV-2 spreads mainly through respiratory droplets and kept mutating as it spread [1], [2]
- **Delta** and **Omicron** spread faster and further than any earlier strain [3], [4]
- Each forced public health strategies to change [5]

RESEARCH QUESTION

How did the transmission dynamics of Delta and Omicron shape, and challenge, public health responses?

Methods

DESIGN Narrative literature review

SOURCES Peer-reviewed studies + WHO, CDC and GISAID data

COMPARED Mutations · spread · prevention · country responses

Public Health Response Timeline

Delta

Omicron

- | | |
|--|--|
| Oct 2020
First detected, India | Nov 24, 2021
First detected, S. Africa |
| May 2021
WHO: variant of concern | Nov 26, 2021
WHO: VOC in 2 days |
| Jul 2021
CDC masking returns | Jan 2022
3rd doses accelerated |
| Sep–Oct 2021
Boosters authorised | Sep 2022
Bivalent vaccines |
| Nov 2021
Displaced by Omicron | May 2023
WHO ends emergency |

Figure 1: Key public health responses after each variant emerged

Results

~56 days

for Delta to dominate 12 major locations [6]

~28 days

for Omicron: nearly twice as fast [7]

30+

spike mutations in Omicron, enabling immune escape [8]

2–3 days

Omicron generation time: too fast for contact tracing [7]




Figure 2: Delta and Omicron case trajectories, 2021–2022

	Delta	Omicron
INFECTS	Lungs	Nose & throat
SEVERITY	Higher	Lower per person
IMMUNE ESCAPE	Moderate	High
MAIN IMPACT	ICU surges	Largest case wave [9]

Discussion

- **Delta → contain.** Vaccines, boosters and masking layered together [7]
- **Omicron → mitigate.** Focus moved from stopping infection to preventing severe illness [8]
- **Resources mattered.** UK reopened, Australia locked down, India faced oxygen shortages [10], [11]
- **Surveillance gap.** Poorer countries often detected variants late [1], [12]

Conclusion

A virus doesn’t need to be **deadlier** to overwhelm health systems. It only needs to spread **faster**.

- Genomic sequencing in every country
- Fair global vaccine access
- Build hospital surge capacity *before* crises
- Flexible, fast-adapting policy [5]

Future research: Long COVID, immunity after repeat infections, AI early-warning models

References

1. S. Roy, “COVID-19 Variants: A Review of the Evolution of the SARS-CoV-2 Genome,” *Front. Microbiol.*, vol. 15, 2024.
2. World Health Organization, “Tracking SARS-CoV-2 Variants,” n.d.
3. S. Kumar et al., “Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike Protein,” *J. Med. Virol.*, 2022.
4. MD Anderson Cancer Center, “COVID-19 New Delta Variant: What You Need to Know,” 2021.
5. D. N. Fisman and A. R. Tuite, “Evaluation of the Relative Virulence of Novel SARS-CoV-2 Variants,” *CMAJ*, 2021.
6. J. He et al., “Global Transmission Dynamics of the Delta Variant,” *Nat. Commun.*, 2022.
7. J. M. Murray et al., “SARS-CoV-2 Delta and Omicron Community Transmission,” *Epidemics*, 2024.
8. X. Zhang et al., “Immune Evasion of SARS-CoV-2 Omicron Variant from mRNA-Based Vaccine-Stimulated Neutralizing Antibodies,” *Cell Rep. Med.*, 2022.
9. A. L. Lundberg et al., “Overlapping Delta and Omicron Outbreaks during the COVID-19 Pandemic,” *JAMA Netw. Open*, 2022.
10. E. A. Meyerowitz and A. Richterman, “SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant,” *Infect. Dis. Clin. N. Am.*, 2022.
11. M. S. Dhar et al., “Genomic Characterization and Epidemiology of an Emerging SARS-CoV-2 Variant in Delhi, India,” *Science*, 2021.
12. A. Banerjee et al., “SARS-CoV-2 Variants and Immune Escape Mechanisms,” *Zoonoses*, 2021.